Filing Details

Accession Number:
0001209191-16-155530
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-12-16 08:08:08
Reporting Period:
2016-12-14
Filing Date:
2016-12-16
Accepted Time:
2016-12-16 08:08:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1008848 Acorda Therapeutics Inc ACOR Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1272354 Ron Cohen 420 Saw Mill River Road
Ardsley NY 10502
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-12-14 40,172 $15.49 519,860 No 4 M Direct
Common Stock Disposition 2016-12-14 39,764 $20.75 480,096 No 4 S Direct
Common Stock Disposition 2016-12-14 408 $21.35 479,688 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2016-12-14 40,172 $0.00 40,172 $15.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-12-21 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 42,940 Indirect Beneficial Ownership in Trust
Footnotes
  1. Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2016 on the expiration date reported withinTable II unless exercised.
  2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.30 to $21.25 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. These shares are held in a grantor retained annuity trust, which was established by the reporting person and of which he is the sole trustee.
  4. The shares subject to these options vested in installments and were fully vested on January 1, 2011.